Clinical trials: Tissue Grafts
Epidermolysis Bullosa
Study of Cellutome System for Treatment of Individual Lesions in EB Pts
Few but persistent wounds often remain even after successful hematopoietic cell transplantation for systemic genodermatosis epidermolysis bullosa (EB).
- Trial name
- NCT02670837
- Testing
- Cellutome Epidermal Harvesting System
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders
RATIONALE: Giving chemotherapy and total-body irradiation before a donor peripheral stem cell transplant helps stop the growth of cancer or abnormal cells.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00544115
- Testing
- busulfan, cyclophosphamide, cyclosporine
- Volunteers
- 260 people
- Sponsor
- City of Hope Medical Center
Psoriasis
A Long Term Study To Evaluate The Safety, Tolerability And Efficacy Of CP-690,550 In Patients With Moderate To Severe Plaque Psoriasis And/Or Psoriatic Arthritis
The main objective of this study is to evaluate the long term safety of CP-690,550 in patients being treated for moderate to severe plaque psoriasis and/or psoriatic arthritis.
- Trial name
- NCT01519089
- Testing
- CP-690,550, CP-690, 550
- Where
- 16 sites in Japan
- Volunteers
- 95 people
- Sponsor
- Pfizer
Oral Lichen Planus, Mucous Membrane Pemphigoid
Dexamethasone Solution and Dexamethasone in Mucolox™
Topical steroid therapy is considered the first line of treatment for Oral Inflammatory Ulcerative Diseases with current treatment regimens requiring multiple application or rinses daily.
- Conditions
- Oral Lichen Planus, Mucous Membrane Pemphigoid, Pemphigus Vulgaris, Chronic Graft-versus-host-disease
- Trial name
- NCT04540133
- Testing
- dexamethasone 0.5mg/5ml solution, dexamethasone 0.5mg/5ml solution in Mucolox™
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Palatal Wound
Comparison of Two Different Low-level Laser Intensity Protocols on the Healing of Palatal Wounds
The aim of this study was to compare two intensities of LLLT on wound healing process of the donor palatine area after CTG removal.
- Trial name
- NCT02580357
- Testing
- Low Level Laser Therapy, GaAlAs laser
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Universidade Estadual Paulista Júlio de Mesquita Filho
Peripheral Nerve Injuries, Neuroma of Nerve Repair
High-Purity Type I Collagen Nerve Wrapping in Peripheral Nerve Procedures: A Prospective Registry
This prospective multicentre observational registry evaluates early clinical outcomes following the use of High-Purity Type I Collagen (HPTC) as a circumferential nerve wrap during peripheral nerve procedures.
- Conditions
- Peripheral Nerve Injuries, Neuroma of Nerve Repair, Nerve Graft; Complications, Mechanical, Peripheral Nerve Decompression Injury
- Trial name
- NCT07360730
- Testing
- High-Purity Type I Collagen (HPTC) Nerve Wrap
- Where
- 2 sites in India
- Volunteers
- 40 people
- Sponsor
- Adichunchanagiri Institute of Medical Sciences, B G Nagara
Coronary Artery Bypass Graft Triple Vessel
Effect of Prewarming on Microcirculatory Response
Intraoperative hypothermia may affect tissue microcirculation and can induce myocardial injury, wound infection, and coagulopathy.
- Trial name
- NCT02186210
- Testing
- prewarming
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Seoul National University Hospital
Gingival Recession
Platelet-rich Fibrin and Connective Tissue Graft in Recession Treatment
The aim of the trial is to evaluate the effectiveness of coronally advanced flap (CAF)+connective tissue graft(CTG)+platelet-rich fibrin(PRF) combination in Miller I and II recession treatment by comparing with CAF+CTG.
- Trial name
- NCT02397122
- Testing
- platelet-rich fibrin, connective tissue graft, coronally advanced flap
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Kırıkkale University
Muscle Loss
Enhanced Bioscaffold for Volumetric Muscle Loss
This is a prospective, single center study conducted at the University of Pittsburgh designed to test the applicability and utility of XenMatrix™ AB Surgical Graft in the restoration of function in the setting of volumetric…
- Trial name
- MTEC-VML (NCT04051242)
- Testing
- XenMatrix™ AB Surgical Graft
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- J. Peter Rubin, MD
Graft-Versus-Host Disease
Tissue Repair in Stem Cell Transplant Recipients
Primary Objective: 1. To determine whether rhG-CSF treatment will increase the frequency of donor-derived cells contributing to repair of damaged epithelial/endothelial or solid organ-specific tissue caused by graft-versus-host…
- Trial name
- NCT00501228
- Testing
- Filgrastim
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- M.D. Anderson Cancer Center
Graft Versus Host Disease, Systemic Scleroderma
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease
This randomized phase II trial is evaluating how well imatinib mesylate works compared to rituximab in treating cutaneous sclerosis in patients with chronic graft- versus-host disease (GVHD).
- Trial name
- NCT01309997
- Testing
- imatinib mesylate, rituximab
- Where
- 10 sites in United States
- Volunteers
- 72 people
- Sponsor
- Lee, Stephanie
Chronic Spontaneous Urticaria
A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Patients
A safety extension study to evaluate the long-term safety of QGE031 240 mg s.c. given every 4 weeks for 52 weeks in Chronic Spontaneous Urticaria (CSU) patients who completed study CQGE031C2201
- Trial name
- NCT02649218
- Testing
- Ligelizumab
- Where
- 67 sites in United States, Australia and 8 more
- Volunteers
- 226 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder
RATIONALE: Cyclosporine eye drops may prevent graft-versus-host disease of the eye in patients who have undergone donor stem cell transplant for hematologic cancer or bone marrow failure disorder.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00755040
- Testing
- cyclosporine ophthalmic emulsion
- Where
- 5 sites in United States
- Volunteers
- 164 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant
RATIONALE: Lithium carbonate may be an effective treatment for intestinal graft-versus-host disease caused by a donor stem cell transplant.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- GVHD (NCT00408681)
- Testing
- lithium carbonate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Fred Hutchinson Cancer Center
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer
This phase II trial studies how well tacrolimus and mycophenolate mofetil works in preventing graft-versus-host disease in patients who have undergone total-body irradiation (TBI) with or without fludarabine phosphate followed by…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT00089011
- Testing
- fludarabine phosphate, total-body irradiation, mycophenolate mofetil
- Where
- 5 sites in United States, Italy
- Volunteers
- 150 people
- Sponsor
- Fred Hutchinson Cancer Center
Degenerative Joint Disease, Congenital Deformity
Augment® Injectable Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Hindfoot Fusions
STUDY OBJECTIVES: To demonstrate equivalent clinical and radiologic outcomes as "gold standard" (Autologous Bone Graft) in a representative clinical model (hindfoot fusions) STUDY HYPOTHESIS: Augment® Injectable is an equivalent…
- Conditions
- Degenerative Joint Disease, Congenital Deformity, Arthritis, Osteoarthritis
- Trial name
- NCT01305356
- Testing
- Augment® Injectable Bone Graft, Autologous bone graft
- Where
- 25 sites in United States, Canada
- Volunteers
- 299 people
- Sponsor
- BioMimetic Therapeutics
Psoriasis, Skin Diseases
A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis
This is a dose-ranging study designed to investigate the efficacy and safety of Baricitinib in the treatment of participants with moderate to severe, chronic plaque psoriasis as assessed by the Psoriasis Area and Severity Index…
- Conditions
- Psoriasis, Skin Diseases, Skin Diseases, Papulosquamous
- Trial name
- NCT01490632
- Testing
- Baricitinib
- Where
- 35 sites in United States, Canada and 2 more
- Volunteers
- 271 people
- Sponsor
- Eli Lilly and Company
Psoriasis, Plaque Psoriasis
Study to Evaluate Safety and Efficacy of Oral MP1032 in Psoriasis Patients
This Phase IIa study is designed to assess the safety, tolerability and pharmacokinetics of oral MP1032 in patients with moderate to severe psoriasis over a period of 6 weeks.
- Trial name
- NCT02908347
- Testing
- MP1032
- Where
- 4 sites in Germany
- Volunteers
- 46 people
- Sponsor
- MetrioPharm AG
Chronic Spontaneous Urticaria
Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU
This is a placebo and active-controlled phase 2b dose-finding study to evaluate efficacy and safety of QGE031 monthly subcutaneous injections as add-on therapy in patients with Chronic Spontaneous Urticaria.
- Trial name
- NCT02477332
- Testing
- QGE031, Omalizumab
- Where
- 82 sites in United States, Australia and 8 more
- Volunteers
- 382 people
- Sponsor
- Novartis Pharmaceuticals
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia
Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD
This phase II trial is for patients with acute lymphocytic leukemia, acute myeloid leukemia, myelodysplastic syndrome or chronic myeloid leukemia who have been referred for a peripheral blood stem cell transplantation to treat…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Undifferentiated Leukemia
- Trial name
- NCT02220985
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Fludarabine Phosphate
- Where
- 2 sites in United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center